eCite Digital Repository

Associations of disease modifying therapies with COVID-19 severity in Multiple Sclerosis

Citation

Simpson-Yap, S and De Brouwer, E and Kalincik, T and Rijke, N and Hillert, JA and Walton, C and Edan, G and Moreau, Y and Spelman, T and Geys, L and Parciak, T and Gautrais, C and Lazovski, N and Pirmani, A and Ardeshirdavanai, A and Forsberg, L and Glaser, A and McBurney, R and Schmidt, H and Bergmann, AB and Braune, S and Stahmann, A and Middleton, R and Salter, A and Fox, RJ and Van Der Walt, A and Butzkueven, H and Alroughani, R and Ozakbas, S and Rojas, JI and Van Der Mei, I and Nag, N and Ivanov, R and Sciascia Do Olival, G and Dias, AE and Magyari, M and Brum, D and Mendes, MF and Alonso, RN and Nicholas, RS and Bauer, J and Chertcoff, AS and Zabalza, A and Arrambide, G and Fidao, A and Comi, G and Peeters, L, Associations of disease modifying therapies with COVID-19 severity in Multiple Sclerosis, Neurology, 97, (19) pp. E1870-E1885. ISSN 0028-3878 (2021) [Refereed Article]


Preview
PDF (Published version)
690Kb
  

Copyright Statement

Copyright 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License International (CC BY 4.0) license, (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: doi:10.1212/WNL.0000000000012753

Abstract

Background and objectives: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS.

Methods: Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1-12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score.

Results: Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01-2.41; aOR 2.43, 95% CI 1.48-4.02) and ICU admission (aOR 2.30, 95% CI 0.98-5.39; aOR 3.93, 95% CI 1.56-9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54-10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29-2.38; aOR 2.76, 95% CI 1.87-4.07) and ICU admission (aOR 2.55, 95% CI 1.49-4.36; aOR 4.32, 95% CI 2.27-8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09-12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13-3.07; aOR 2.88, 95% CI 1.68-4.92) and ICU admission (aOR 2.13, 95% CI 0.85-5.35; aOR 3.23, 95% CI 1.17-8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71-17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity.

strong>Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19.

Item Details

Item Type:Refereed Article
Keywords:Covid-19, Multiple Sclerosis
Research Division:Biomedical and Clinical Sciences
Research Group:Clinical sciences
Research Field:Clinimetrics
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Simpson-Yap, S (Dr Steve Simpson JR)
ID Code:152395
Year Published:2021
Web of Science® Times Cited:58
Deposited By:Medicine
Deposited On:2022-08-18
Last Modified:2022-09-30
Downloads:0

Repository Staff Only: item control page